NEW YORK (GenomeWeb News) – Monogram Biosciences said today that the Dana-Farber Cancer Institute has agreed to evaluate its HERmark breast cancer assay in metastatic breast cancer.
 
The goal of the project is to test HERmark cutoff values and determine whether the assay is better than conventional methods for identifying metastatic breast cancer patients who are susceptible to Genentech’s Herceptin (trastuzumab) treatment.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.